MA71409A - Constructions d'anticorps pour dll3 et cd3 - Google Patents

Constructions d'anticorps pour dll3 et cd3

Info

Publication number
MA71409A
MA71409A MA71409A MA71409A MA71409A MA 71409 A MA71409 A MA 71409A MA 71409 A MA71409 A MA 71409A MA 71409 A MA71409 A MA 71409A MA 71409 A MA71409 A MA 71409A
Authority
MA
Morocco
Prior art keywords
dll3
antibody constructs
constructs
antibody
Prior art date
Application number
MA71409A
Other languages
English (en)
Inventor
Tobias Raum
Peter Kufer
Patrick Hoffmann
Jochen PENDZIALEK
Claudia Bluemel
Christoph DAHLHOFF
Ralf Lutterbuese
Elisabeth NAHRWOLD
Original Assignee
Amgen Research (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research (Munich) Gmbh filed Critical Amgen Research (Munich) Gmbh
Publication of MA71409A publication Critical patent/MA71409A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA71409A 2015-07-31 2016-08-01 Constructions d'anticorps pour dll3 et cd3 MA71409A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199930P 2015-07-31 2015-07-31
US201662290896P 2016-02-03 2016-02-03
EP24159281.5A EP4382169A3 (fr) 2015-07-31 2016-08-01 Constructions d'anticorps pour dll3 et cd3

Publications (1)

Publication Number Publication Date
MA71409A true MA71409A (fr) 2025-04-30

Family

ID=56800252

Family Applications (2)

Application Number Title Priority Date Filing Date
MA71409A MA71409A (fr) 2015-07-31 2016-08-01 Constructions d'anticorps pour dll3 et cd3
MA42530A MA42530B1 (fr) 2015-07-31 2016-08-01 Constructions d'anticorps bispécifiques se liant à dll3 et à cd3

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA42530A MA42530B1 (fr) 2015-07-31 2016-08-01 Constructions d'anticorps bispécifiques se liant à dll3 et à cd3

Country Status (36)

Country Link
US (6) US10294300B2 (fr)
EP (3) EP4382169A3 (fr)
JP (5) JP6824245B2 (fr)
KR (4) KR20250008980A (fr)
CN (3) CN108271376B (fr)
AU (3) AU2016302569B2 (fr)
CA (2) CA2986848C (fr)
CL (2) CL2018000267A1 (fr)
CO (1) CO2018000877A2 (fr)
CR (1) CR20180066A (fr)
CY (1) CY1124472T1 (fr)
DK (1) DK3328889T3 (fr)
ES (1) ES2884211T3 (fr)
HR (1) HRP20211073T1 (fr)
HU (1) HUE055112T2 (fr)
IL (3) IL320033A (fr)
JO (1) JO3671B1 (fr)
LT (1) LT3328889T (fr)
MA (2) MA71409A (fr)
MD (1) MD3328889T2 (fr)
MX (2) MX385605B (fr)
MY (1) MY184895A (fr)
NZ (1) NZ737339A (fr)
PE (1) PE20181152A1 (fr)
PH (1) PH12018500241A1 (fr)
PL (1) PL3328889T3 (fr)
PT (1) PT3328889T (fr)
RS (1) RS62248B1 (fr)
SG (1) SG10201911548QA (fr)
SI (1) SI3328889T1 (fr)
SM (1) SMT202100482T1 (fr)
TN (1) TN2017000549A1 (fr)
TW (2) TW202346349A (fr)
UA (1) UA126964C2 (fr)
WO (1) WO2017021349A1 (fr)
ZA (1) ZA202006983B (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4059964A1 (fr) * 2007-04-03 2022-09-21 Amgen Research (Munich) GmbH Domaine de liaison inter-especes
WO2010037835A2 (fr) * 2008-10-01 2010-04-08 Micromet Ag Anticorps monocaténaire bispécifique pscaxcd3 (cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 ou fapalpha xcd3), spécifique d'espèces croisées
US10981998B2 (en) 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
SI2530091T1 (en) 2010-01-29 2018-06-29 Chugai Seiyaku Kabushiki Kaisha PROTITELO ANTI-DLL3
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
TWI712421B (zh) 2013-11-11 2020-12-11 日商中外製藥股份有限公司 含改變的抗體可變區之抗原結合分子
TWI880146B (zh) 2014-11-11 2025-04-11 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
EA037065B1 (ru) 2014-11-26 2021-02-01 Ксенкор, Инк. Гетеродимерные антитела, связывающие cd3 и cd38
HUE055115T2 (hu) 2014-11-26 2021-10-28 Xencor Inc CD3-at és CD20-at kötõ heterodimer antitestek
KR101997241B1 (ko) 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TW202346349A (zh) * 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
KR102688969B1 (ko) 2016-02-03 2024-07-30 암젠 리서치 (뮌헨) 게엠베하 Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
WO2017134158A1 (fr) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Constructions d'anticorps impliquant des cellules t bispécifiques psma et cd3
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR20240023449A (ko) 2017-02-08 2024-02-21 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
JP7685821B2 (ja) 2017-02-20 2025-05-30 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質
MX2019012198A (es) 2017-04-11 2020-01-21 Inhibrx Inc Constructos de polipéptidos multiespecíficos que tienen unión limitada a cd3 y métodos de utilización de los mismos.
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2019028316A1 (fr) 2017-08-03 2019-02-07 Amgen Inc. Mutéines d'interleukine-21 et méthodes de traitement
AR112797A1 (es) 2017-09-08 2019-12-11 Amgen Inc Inhibidores de kras g12c y métodos para utilizarlos
WO2019075359A1 (fr) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Protéines trispécifiques et méthodes d'utilisation
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EP3720963A4 (fr) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène comprenant une région variable d'anticorps modifiée se liant à cd3 et cd137
JP7314146B2 (ja) * 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
WO2019139987A1 (fr) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Constructions de liaison à la calréticuline et lymphocytes t modifiés pour le traitement de maladies
ES2941740T3 (es) 2018-01-12 2023-05-25 Amgen Inc Anticuerpos anti-PD-1 y métodos de tratamiento
PT3749346T (pt) 2018-02-08 2024-09-05 Dragonfly Therapeutics Inc Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d
KR20200118824A (ko) 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
CA3091424A1 (fr) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Proteines de liaison multi-specifiques qui se lient a cd33, nkg2d et cd16, et procedes d'utilisation
US20220025037A1 (en) * 2018-04-03 2022-01-27 Dragonfly Therapeutics, Inc. Antibody variable domains targeting dll3, and use thereof
EP3773676A4 (fr) * 2018-04-03 2022-05-18 Dragonfly Therapeutics, Inc. Protéines de liaison à nkg2d, cd16 et à un antigène associé à des tumeurs, des mdsc et/ou des tam
CA3095920A1 (fr) * 2018-04-10 2019-10-17 Amgen Inc. Recepteurs chimeres pour dll3 et leurs procedes d'utilisation
US20190330366A1 (en) 2018-04-11 2019-10-31 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
JP7455388B2 (ja) * 2018-05-08 2024-03-26 フェインズ セラピューティクス，インコーポレーテッド 抗ｄｌｌ３抗体及びその使用
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
EP3827019A1 (fr) 2018-07-24 2021-06-02 Inhibrx, Inc. Constructions polypeptidiques multispécifiques contenant un domaine de liaison à cd3 contraint et une région de liaison à un récepteur, et leurs procédés d'utilisation
US12435137B2 (en) 2018-08-03 2025-10-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other
SG11202101298XA (en) 2018-08-08 2021-03-30 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3833392A4 (fr) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
BR112021005769A2 (pt) * 2018-09-25 2021-07-06 Harpoon Therapeutics Inc proteínas de ligação a dll3 e métodos de uso
JP7611820B2 (ja) * 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
CN120623346A (zh) 2018-10-11 2025-09-12 因荷布瑞克斯生物科学公司 Pd-1单结构域抗体及其治疗组合物
CN111138542B (zh) * 2018-11-01 2022-09-23 山东新时代药业有限公司 双特异性抗体及其用途
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
SG11202108955QA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Antibody molecules that bind to nkp30 and uses thereof
SG11202108011UA (en) 2019-03-01 2021-08-30 Allogene Therapeutics Inc Dll3 targeting chimeric antigen receptors and binding agents
BR112021016272A2 (pt) * 2019-04-08 2021-11-09 Phanes Therapeutics Inc Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos
CA3142165A1 (fr) * 2019-06-07 2020-12-10 Amgen Inc. Constructions de liaison bispecifiques a lieurs clivables de maniere selective
TWI889320B (zh) 2019-07-05 2025-07-01 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
US12435148B2 (en) 2019-07-12 2025-10-07 The Research Foundation For The State University Of New York Compositions and methods to block and bind CXCR4 to modulate cellular function
EP3819312A1 (fr) * 2019-11-10 2021-05-12 Amgen, Inc Régime de dosage pour agents anti-dll3
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
US20220411497A1 (en) * 2019-12-17 2022-12-29 Phanes Therapeutics, Inc. Bispecific Antibodies with Alternatively Matched Interchain Cysteines and Uses Thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
MX2022009306A (es) 2020-01-29 2022-09-26 Inhibrx Inc Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
WO2021155380A1 (fr) * 2020-01-31 2021-08-05 Gensun Biopharma Inc. Agents de mise en contact de lymphocytes t bispécifiques
US12486331B2 (en) * 2020-01-31 2025-12-02 Gensun Biopharma Inc. Bispecific T cell engagers
CN116096751A (zh) * 2020-02-25 2023-05-09 璟尚生物制药公司 三特异性t细胞接合器
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
CR20250287A (es) * 2020-03-31 2025-08-28 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta (dll3) y sus usos (divisional exp. 2022-0541)
CA3177024A1 (fr) 2020-05-06 2021-11-11 Dragonfly Therapeutics, Inc. Proteines se liant a nkg2d, cd16 et clec12a
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CN116157416A (zh) 2020-08-25 2023-05-23 吉利德科学公司 靶向hiv的多特异性抗原结合分子及其使用方法
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
TW202233672A (zh) * 2020-10-22 2022-09-01 美商健生生物科技公司 包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
CN116323671A (zh) * 2020-11-06 2023-06-23 安进公司 具有增加的选择性的多靶向性双特异性抗原结合分子
WO2022187539A1 (fr) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Méthodes de traitement du cancer à l'aide de protéines de liaison multi-spécifiques qui se lient à nkg2d, à cd16 et à un antigène associé à une tumeur
MX2023010499A (es) 2021-03-09 2023-09-18 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cldn6.
JP7711208B2 (ja) * 2021-05-08 2025-07-22 上海齊魯制藥研究中心有限公司 Ｄｌｌ３に対する結合分子及びその使用
WO2022240688A1 (fr) * 2021-05-10 2022-11-17 Amgen Inc. Schéma posologique pour polythérapie ciblant dll3 et pd-1
KR20240027701A (ko) * 2021-06-30 2024-03-04 암젠 인크 동결건조 제형의 재구성 방법
CN113461821B (zh) * 2021-09-03 2021-12-28 苏州近岸蛋白质科技股份有限公司 抗cd3人源化抗体
AU2022345323A1 (en) * 2021-09-17 2024-03-28 WuXi Biologics Ireland Limited D3-binding molecules and uses thereof
WO2023053272A1 (fr) 2021-09-29 2023-04-06 Chugai Seiyaku Kabushiki Kaisha Utilisations de molécules de liaison à un antigène multispécifiques ciblant dll3
WO2023151613A1 (fr) * 2022-02-10 2023-08-17 上海齐鲁制药研究中心有限公司 Molécule bispécifique de liaison à l'antigène et son utilisation
US12365743B2 (en) 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies
CN119256017A (zh) * 2022-06-23 2025-01-03 江苏恒瑞医药股份有限公司 特异性结合dll3和cd3的抗原结合分子及其医药用途
CN120303300A (zh) * 2022-12-08 2025-07-11 安进公司 治疗表达dll3的癌症的方法
WO2025035356A1 (fr) * 2023-08-14 2025-02-20 Zhejiang Shimai Pharmaceutical Co., Ltd. Anticorps dirigés contre dll3 et leurs utilisations
WO2025131024A1 (fr) * 2023-12-22 2025-06-26 江苏恒瑞医药股份有限公司 Composition pharmaceutique comprenant un anticorps bispécifique se liant spécifiquement à dll3 et cd3
WO2025146127A1 (fr) * 2024-01-05 2025-07-10 海南先声再明医药股份有限公司 Anticorps bispécifique dirigé contre dll3 et cd3 et utilisation d'anticorps bispécifique
CN120647761A (zh) * 2024-03-15 2025-09-16 信达生物制药(苏州)有限公司 抗dll3抗体及其用途
WO2025217101A2 (fr) 2024-04-09 2025-10-16 Amgen Inc. Anticorps agonistes à chaîne lourde anti-il-2rbg

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447A (en) 1846-04-04 Car- wheel
US556A (en) 1838-01-09 Machine foe
US5013A (en) 1847-03-13 Improvement in apparatus for the manufacture of malleable iron
US1985A (en) 1841-02-18 Charles m
US233A (en) 1837-06-14 Improvement in plows
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (fr) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Procede de fixation d'une proteine sur un substrat
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (fr) 1977-02-17 1981-01-20 Hideo Hirohara Traduction non-disponible
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
ATE108965T1 (de) 1987-12-09 1994-08-15 Omron Tateisi Electronics Co Induktives datenübertragungssystem.
US5159016A (en) 1987-12-28 1992-10-27 Nippon Petrochemicals Company, Limited Process for preparing thermoplastic resin composition
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
WO1991010741A1 (fr) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation d'anticorps xenogeniques
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2090473A1 (fr) 1990-08-29 1992-03-01 Robert M. Kay Recombinaison homologue dans des cellules mammaliennes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2142801T3 (es) 1991-03-11 2000-05-01 Univ Georgia Res Found Clonacion y expresion de luciferasa de renilla.
WO1992022670A1 (fr) 1991-06-12 1992-12-23 Genpharm International, Inc. Detection precoce d'embryons transgeniques
WO1992022645A1 (fr) 1991-06-14 1992-12-23 Genpharm International, Inc. Animaux transgeniques non humains presentant une deficience immunitaire
CA2103059C (fr) 1991-06-14 2005-03-22 Paul J. Carter Methode de production d'anticorps humanises
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0746609A4 (fr) 1991-12-17 1997-12-17 Genpharm Int Animaux transgeniques non humains capables de produire des anticorps heterologues
WO1993015722A1 (fr) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Liberation controlee de produits pharmaceutiques a partir de microparticules poreuses preformees
CA2135313A1 (fr) 1992-06-18 1994-01-06 Theodore Choi Methodes pour l'obtention d'animaux transgeniques, comportant un chromosome artificiel de levure
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK0672141T3 (da) 1992-10-23 2003-06-10 Immunex Corp Fremgangsmåder til fremstilling af opløselige, oligomere proteiner
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
CA2161351C (fr) 1993-04-26 2010-12-21 Nils Lonberg Animaux transgeniques, pouvant produire des anticorps heterologues
US7045128B2 (en) 1993-05-24 2006-05-16 Immunex Corporation Antibodies against flt3-ligand
DE69435112D1 (de) 1993-09-10 2008-08-21 Univ Columbia Verwendung von grünem fluoreszenzprotein
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
WO1995021191A1 (fr) 1994-02-04 1995-08-10 William Ward Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
CA2230759C (fr) 1995-08-29 2012-02-21 Kirin Beer Kabushiki Kaisha Animal chimerique et procede pour le produire
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
IL129767A0 (en) 1996-12-12 2000-02-29 Prolume Ltd Apparatus and method for detecting and identifying infectious agents
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
JP2002507410A (ja) 1998-03-27 2002-03-12 プロルーム・リミテッド ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用
EP1071752B1 (fr) 1998-04-21 2003-07-09 Micromet AG Polypeptides specifiques a cd19 et cd3 et leurs utilisations
AU5728999A (en) 1998-07-28 2000-02-21 Micromet Ag Heterominibodies
US7254167B2 (en) 1998-10-30 2007-08-07 Broadcom Corporation Constellation-multiplexed transmitter and receiver
CA2342967A1 (fr) 1998-12-08 2000-06-15 Biovation Limited Modification de l'immunogenicite de proteines
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
AU2002348263B2 (en) 2001-11-30 2008-10-16 Amgen Fremont Inc. Transgenic animals bearing human IgLamda light chain genes
US8486859B2 (en) 2002-05-15 2013-07-16 Bioenergy, Inc. Use of ribose to enhance plant growth
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US7904068B2 (en) 2003-06-06 2011-03-08 At&T Intellectual Property I, L.P. System and method for providing integrated voice and data services utilizing wired cordless access with unlicensed spectrum and wired access with licensed spectrum
RU2401843C2 (ru) 2003-10-16 2010-10-20 Микромет Аг Полиспецифические деиммунизирующие cd3-связующие
EP2228698B1 (fr) 2005-03-14 2012-06-27 Omron Corporation Système de contrôle programmable
EP1909831A4 (fr) 2005-06-14 2013-02-20 Amgen Inc Préparations de protéines à tamponnage spontané
US8234145B2 (en) 2005-07-12 2012-07-31 International Business Machines Corporation Automatic computation of validation metrics for global logistics processes
BRPI0604215A (pt) 2005-08-17 2007-04-10 Biosigma Sa método para projetar oligonucleotìdeos para técnicas de biologia molecular
EP1940881B1 (fr) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations
JP2007122396A (ja) 2005-10-27 2007-05-17 Hitachi Ltd ディスクアレイ装置及びその障害対応検証方法
WO2007111733A2 (fr) * 2005-12-16 2007-10-04 Genentech, Inc. Méthode de diagnostic, de pronostic et de traitement du gliome
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
US7919297B2 (en) 2006-02-21 2011-04-05 Cornell Research Foundation, Inc. Mutants of Aspergillus niger PhyA phytase and Aspergillus fumigatus phytase
US7574748B2 (en) 2006-03-07 2009-08-18 Nike, Inc. Glove with support system
US7990860B2 (en) 2006-06-16 2011-08-02 Harris Corporation Method and system for rule-based sequencing for QoS
US8430938B1 (en) 2006-07-13 2013-04-30 The United States Of America As Represented By The Secretary Of The Navy Control algorithm for autothermal reformer
KR101146588B1 (ko) 2006-08-11 2012-05-16 삼성전자주식회사 Ｆｉｎ 구조체 및 이를 이용한 핀 트랜지스터의 제조방법
CN100589507C (zh) 2006-10-30 2010-02-10 华为技术有限公司 一种拨号提示系统及方法
US7466008B2 (en) 2007-03-13 2008-12-16 Taiwan Semiconductor Manufacturing Company, Ltd. BiCMOS performance enhancement by mechanical uniaxial strain and methods of manufacture
EP2155783B2 (fr) * 2007-04-03 2022-10-19 Amgen Research (Munich) GmbH Domaine de liaison contre cd3-epsilon specifique d'especes croisees
EP4059964A1 (fr) 2007-04-03 2022-09-21 Amgen Research (Munich) GmbH Domaine de liaison inter-especes
US8209741B2 (en) 2007-09-17 2012-06-26 Microsoft Corporation Human performance in human interactive proofs using partial credit
US8464584B2 (en) 2007-10-19 2013-06-18 Food Equipment Technologies Company, Inc. Beverage dispenser with level measuring apparatus and display
DE102008057648A1 (de) 2007-11-29 2009-06-04 Luk Lamellen Und Kupplungsbau Beteiligungs Kg Kraftübertragungsvorrichtung, insbesondere zur Leistungsübertragung zwischen einer Antriebsmaschine und einem Abtrieb
US8376279B2 (en) 2008-01-23 2013-02-19 Aurora Flight Sciences Corporation Inflatable folding wings for a very high altitude aircraft
WO2009127691A1 (fr) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capables de se lier à des protéines sériques et composés, constructions et polypeptides les comprenant
US10981998B2 (en) 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
US8486853B2 (en) 2009-03-04 2013-07-16 Nissan Motor Co., Ltd. Exhaust gas purifying catalyst and method for manufacturing the same
US8463191B2 (en) 2009-04-02 2013-06-11 Qualcomm Incorporated Beamforming options with partial channel knowledge
EP3421491A3 (fr) 2009-10-30 2019-03-27 Albumedix Ltd Variantes d'albumine
SI2530091T1 (en) 2010-01-29 2018-06-29 Chugai Seiyaku Kabushiki Kaisha PROTITELO ANTI-DLL3
EP2635598A1 (fr) 2010-11-01 2013-09-11 Novozymes Biopharma DK A/S Variants d'albumine
CN103298648B (zh) 2010-12-30 2016-04-13 C.劳勃.汉默斯坦两合有限公司 适于机动车辆座椅的包括两对导轨的纵向调节装置
CN110272484A (zh) 2011-05-05 2019-09-24 阿尔布梅迪克斯医疗有限公司 白蛋白变体
WO2013026837A1 (fr) 2011-08-23 2013-02-28 Roche Glycart Ag Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t.
AR087608A1 (es) 2011-08-23 2014-04-03 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
PL2817338T3 (pl) * 2012-02-24 2017-12-29 Abbvie Stemcentrx Llc Modulatory DLL3 i sposoby zastosowania
JP6441682B2 (ja) 2012-03-16 2018-12-19 アルブミディクス リミティド アルブミン変種
CN105452290A (zh) 2012-11-08 2016-03-30 诺维信生物制药丹麦公司 白蛋白变体
US9243058B2 (en) * 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP3424952A1 (fr) 2013-03-15 2019-01-09 Amgen, Inc Anticorps bispécifiques hétérodimériques
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置
EP3733710A1 (fr) 2013-09-25 2020-11-04 Amgen, Inc Anticorps v-c-fc-v-c hétérodimeriques
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
CN104592392B (zh) * 2015-01-21 2018-08-28 武汉友芝友生物制药有限公司 一种双特异性抗体EpCAM×CD3的构建及应用
EP3174901B1 (fr) * 2014-07-31 2019-06-26 Amgen Research (Munich) GmbH Constructions optimisées d'anticorps monocaténaires, bispécifiques, spécifiques d'espèces croisées
AR101669A1 (es) * 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
US10105142B2 (en) 2014-09-18 2018-10-23 Ethicon Llc Surgical stapler with plurality of cutting elements
TW202346349A (zh) * 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI829617B (zh) * 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
WO2017134158A1 (fr) * 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Constructions d'anticorps impliquant des cellules t bispécifiques psma et cd3
KR102688969B1 (ko) * 2016-02-03 2024-07-30 암젠 리서치 (뮌헨) 게엠베하 Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly

Also Published As

Publication number Publication date
US20190263907A1 (en) 2019-08-29
CN114292336A (zh) 2022-04-08
CL2018000267A1 (es) 2018-10-05
UA126964C2 (uk) 2023-03-01
CA3212157A1 (fr) 2017-02-09
CN108271376A (zh) 2018-07-10
TW201708261A (zh) 2017-03-01
EP3328889B1 (fr) 2021-06-23
HRP20211073T1 (hr) 2021-10-01
KR20250008981A (ko) 2025-01-16
CN114292336B (zh) 2024-10-18
WO2017021349A1 (fr) 2017-02-09
US20210309743A1 (en) 2021-10-07
JP7166368B2 (ja) 2022-11-07
NZ737339A (en) 2022-09-30
TN2017000549A1 (en) 2019-04-12
US10294300B2 (en) 2019-05-21
HK1249525A1 (zh) 2018-11-02
JP2021000088A (ja) 2021-01-07
CO2018000877A2 (es) 2018-04-19
PE20181152A1 (es) 2018-07-17
MY184895A (en) 2021-04-30
SMT202100482T1 (it) 2021-09-14
KR20180033501A (ko) 2018-04-03
CA2986848C (fr) 2023-12-05
NZ778573A (en) 2025-06-27
US12304952B2 (en) 2025-05-20
US20230312717A1 (en) 2023-10-05
SI3328889T1 (sl) 2021-09-30
JP2021061859A (ja) 2021-04-22
ES2884211T3 (es) 2021-12-10
EP3328889A1 (fr) 2018-06-06
RS62248B1 (sr) 2021-09-30
PT3328889T (pt) 2021-08-25
US20200332002A1 (en) 2020-10-22
MX2018001154A (es) 2018-05-23
TW202346349A (zh) 2023-12-01
CN108271376B (zh) 2021-11-12
IL320033A (en) 2025-06-01
KR102404077B1 (ko) 2022-06-02
JP2022191477A (ja) 2022-12-27
SG10201911548QA (en) 2020-01-30
CY1124472T1 (el) 2022-07-22
PL3328889T3 (pl) 2021-12-06
IL256871B (en) 2022-10-01
IL296409B1 (en) 2025-06-01
DK3328889T3 (da) 2021-08-23
NZ778605A (en) 2025-05-30
JP2018527908A (ja) 2018-09-27
CR20180066A (es) 2018-05-29
EP4382169A2 (fr) 2024-06-12
JP6827583B2 (ja) 2021-02-10
MX385605B (es) 2025-03-18
US10683351B2 (en) 2020-06-16
MA42530B1 (fr) 2021-09-30
IL256871A (en) 2018-03-29
HUE055112T2 (hu) 2021-10-28
EP3865514A1 (fr) 2021-08-18
ZA202006983B (en) 2023-03-29
TWI793062B (zh) 2023-02-21
AU2016302569A1 (en) 2017-12-07
US11591396B2 (en) 2023-02-28
AU2025202484A1 (en) 2025-05-01
MX2021009793A (es) 2021-09-08
BR112018000475A2 (pt) 2018-09-18
CA2986848A1 (fr) 2017-02-09
IL296409A (en) 2022-11-01
EP4382169A3 (fr) 2024-10-09
LT3328889T (lt) 2021-08-10
AU2022268314A1 (en) 2022-12-15
JP6824245B2 (ja) 2021-02-03
JO3671B1 (ar) 2020-08-27
JP2025106535A (ja) 2025-07-15
MA42530A (fr) 2021-03-24
PH12018500241A1 (en) 2018-08-13
KR102749378B1 (ko) 2025-01-03
US12435139B2 (en) 2025-10-07
JP7668256B2 (ja) 2025-04-24
MD3328889T2 (ro) 2021-10-31
IL296409B2 (en) 2025-10-01
CL2020003046A1 (es) 2021-04-09
KR20250008980A (ko) 2025-01-16
US20250340639A1 (en) 2025-11-06
US20170037130A1 (en) 2017-02-09
CN119371549A (zh) 2025-01-28
AU2016302569B2 (en) 2022-08-25
IL256871B2 (en) 2023-02-01
KR20220075455A (ko) 2022-06-08

Similar Documents

Publication Publication Date Title
MA71409A (fr) Constructions d'anticorps pour dll3 et cd3
FR24C1050I1 (fr) Récepteurs d'antigènes chimériques basés sur des anticorps à domaine unique et leurs méthodes d'utilisation
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
MA49043A (fr) Formulation stable d'anticorps
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA44054A (fr) Plateforme d'anticorps bispécifique
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP3359573A4 (fr) Marquage d'anticorps
EP3383430A4 (fr) Anticorps et leurs méthodes d'utilisation
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA44659A (fr) Anticorps anti-tim-3 et compositions
EP3473649A4 (fr) Anticorps monoclonal anti-cd47 et application correspondante
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA44381A (fr) Format d'anticorps hétérodimères multispécifiques
EP3383431A4 (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
MA48462A (fr) Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci